Clinical trial
A New Oral Treatment For Type II Diabetes Mellitus
NCT00111800 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00111800 |
|---|---|
| Title | A New Oral Treatment For Type II Diabetes Mellitus |
| Official title | A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of Denagliptin, Administered Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus Followed by a 12-week Active Treatment… |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg |
| Enrollment | 375 |
| Start date | Apr 28, 2005 |
| Primary completion | Jul 1, 2006 |
| Completion | Jul 21, 2006 |
| First posted | May 26, 2005 |
| Last update posted | Mar 21, 2018 |
| Countries | Canada, Czechia, Finland, Germany, Greece, Latvia, Puerto Rico, Romania, Sweden, United States |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: